SK BioscienceSK바이오사이언스
302440 · KOSPI · ₩302440 · SK바이오사이언스
₩32,150▲ ₩400 (1.26%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩651B | ₩268B | ₩370B | ₩457B | ₩929B |
| Cost of sales | ₩575B | ₩237B | ₩227B | ₩217B | ₩359B |
| Gross profit | ₩76B | ₩31B | ₩142B | ₩240B | ₩570B |
| Operating income | −₩124B | −₩138B | −₩12B | ₩115B | ₩474B |
| Net income | −₩56B | −₩50B | ₩22B | ₩122B | ₩355B |
| Net income to shareholders | −₩57B | −₩54B | ₩22B | ₩122B | ₩355B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩3T | ₩2.8T | ₩1.9T | ₩2.1T | ₩2.1T |
| Current assets | ₩1.2T | ₩1.6T | ₩1.4T | ₩1.8T | ₩1.8T |
| Cash and equivalents | ₩106B | ₩313B | ₩127B | ₩225B | ₩98B |
| Total liabilities | ₩918B | ₩821B | ₩149B | ₩400B | ₩509B |
| Current liabilities | ₩326B | ₩311B | ₩136B | ₩380B | ₩460B |
| Borrowings | ₩465B | ₩383B | ₩0 | ₩84B | ₩95B |
| Total equity | ₩2T | ₩2T | ₩1.7T | ₩1.7T | ₩1.6T |
| Shareholders' equity | ₩1.8T | ₩1.8T | ₩1.7T | ₩1.7T | ₩1.6T |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩103B | −₩128B | ₩29B | −₩125B | ₩537B |
| Capital spending | ₩183B | ₩164B | ₩43B | ₩72B | ₩43B |
| Free cash flow | −₩81B | −₩292B | −₩14B | −₩197B | ₩494B |
Consolidated where available. Amounts in won.
Also known as: SK Bioscience / SK바이오사이언스 / 302440 / KRX:302440
Source: KRX statistical information